Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Experimental and Therapeutic Medicine

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/etm.2017.4562PMID 28673007PMCID PMC5488714
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New strategies for cancer immunotherapy: targeting regulatory T cells

  2017cited by this paper
• Age and gender leucocytes variances and references values generated using the standardized ONE‐Study protocol

  2016cited by this paper
• Leading Causes of Cancer Mortality - Caribbean Region, 2003-2013.

  2016cited by this paper
• Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection

  2016influential reference
• Cancer treatment and survivorship statistics, 2016

  2016cited by this paper
• Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.

  2015cited by this paper
• NK cells regulating T cell responses: mechanisms and outcome.

  2015cited by this paper
• Palliative thoracic radiotherapy for patients with advanced non-small cell lung cancer and poor performance status.

  2015cited by this paper
• Tumor-derived CD4+CD25+ Tregs inhibit the maturation and antigen-presenting function of dendritic cells.

  2015cited by this paper
• FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer

  2015cited by this paper
• Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.

  2015cited by this paper
• NK cells and exercise: implications for cancer immunotherapy and survivorship.

  2015cited by this paper
• 核苷酸还原酶M1在晚期非小细胞肺癌治疗和预后中的作用

  2015cited by this paper
• Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer

  2015cited by this paper
• Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.

  2015cited by this paper
• Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging

  2015cited by this paper
• NK Cell-based Immunotherapies in Pediatric Oncology

  2015cited by this paper
• Human Tumor Antigens and Cancer Immunotherapy

  2015cited by this paper
• Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy

  2015cited by this paper
• Chemotherapeutic targeting of cancer-induced immunosuppressive cells.

  2014cited by this paper
• OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

  2014cited by this paper
• Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

  2014cited by this paper
• NKG2D CARs as Cell Therapy for Cancer

  2014cited by this paper
• Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors

  2014cited by this paper
• FKBP51 increases the tumour-promoter potential of TGF-beta

  2014cited by this paper
• Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer

  2014influential reference
• Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer

  2014cited by this paper
• The Treg/Th17 Paradigm in Lung Cancer

  2014cited by this paper
• Protective effect of CD4(+)CD25(high)CD127(low) regulatory T cells in renal ischemia-reperfusion injury.

  2014cited by this paper
• Regulatory T Cells in Cancer Patients and Their Roles in Cancer Development/Progression

  2014cited by this paper
• Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.

  2014cited by this paper
• Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma

  2013cited by this paper
• IL-15 Improves the Cytotoxicity of Cytokine-induced Killer Cells Against Leukemia Cells by Upregulating CD3+CD56+ Cells and Downregulating Regulatory T Cells As Well As IL-35

  2013cited by this paper
• Depletion of CD4+ CD25+ Regulatory T Cells Promotes CCL21-Mediated Antitumor Immunity

  2013cited by this paper
• Mecanismos de supresión de las células T reguladoras (Treg)

  2013cited by this paper
• Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3

  2013cited by this paper
• Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity

  2013cited by this paper
• Transient Foxp3+ regulatory T‐cell depletion enhances therapeutic anticancer vaccination targeting the immune‐stimulatory properties of NKT cells

  2013cited by this paper
• S-1 plus CIK as second-line treatment for advanced pancreatic cancer

  2013influential reference
• Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells

  2013influential reference
• Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

  2013cited by this paper
• [Mechanisms of suppression of regulatory T-cells (Treg)].

  2013cited by this paper
• Influence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp-70-Derived 14-mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors

  2013influential reference
• Increased frequency and suppressive activity of CD127low/− regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement

  2013cited by this paper
• Implication of TGF-β as a survival factor during tumour development.

  2012cited by this paper
• CD4+CD25+CD127low/− T Cells: A More Specific Treg Population in Human Peripheral Blood

  2012cited by this paper
• Human CD4+CD25(high)CD127 (low/neg) regulatory T cells.

  2012cited by this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cited by this paper
• Cancer treatment and survivorship statistics, 2012

  2012cited by this paper
• Investigation of NK cell function and their modulation in different malignancies

  2012cited by this paper
• [Clinical study on cytokine induced killer cells therapy to laryngeal cancer after radiotherapy].

  2011cited by this paper
• Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer

  2011cited by this paper
• Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity

  2011cited by this paper
• Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

  2010cited by this paper
• Regulatory T cells in cancer.

  2010cited by this paper
• FOXP3+ regulatory T cells in the human immune system

  2010cited by this paper
• [Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma].

  2010cited by this paper
• [Clinical Analysis of Autologous Cytokine-induced Killer Cells Combined with IL-2 for Treating of Elderly Patients with B-cell Malignant Lymphoma].

  2010cited by this paper
• Regulatory T cells in tumor immunity

  2010cited by this paper
• T Regulatory Type 1 Cells in Squamous Cell Carcinoma of the Head and Neck: Mechanisms of Suppression and Expansion in Advanced Disease

  2008cited by this paper
• Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.

  2008cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• NK cell recognition.

  2005cited by this paper
• Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells

  2005cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Topoisomerase I Inhibitors with an Indolocarbazole Structure Transporter as a Transporter of NB-506 and J-107088 , Resistance / Placenta-Specific , ATP-binding Cassette Identification of Breast Cancer Resistant Protein / Mitoxantrone Updated

  2001cited by this paper
• Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

  1999cited by this paper
• Lung carcinoma

  1999cited by this paper
• Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

  1999cited by this paper

• The Therapeutic Potential of Cytokine-Induced Killer in Patients with Cancer

  2024cites this paper
• Molecular characterization and expression analysis of IL-10 and IL-20L genes in swamp eel (Monopterus albus) against Aeromonas veronii infection

  2022cites this paper
• Comparison of international guidelines for early-phase clinical trials of cellular and gene therapy products

  2022cites this paper
• Retrospective analysis of the efficacy of adjuvant cytokine‐induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery

  2022cites this paper
• Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases

  2021cites this paper
• Cytokine-induced Killer T Cells Enhance the Cytotoxicity Against Carboplatin-resistant Ovarian Cancer Cells

  2020cites this paper
• Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma.

  2020cites this paper
• Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment.

  2020cites this paper
• Immunotherapeutic CAR T-Cell Engineering

  2019cites this paper
• Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro

  2019cites this paper
• p‐Hydroxylcinnamaldehyde slows the progression of 4NQO‐induced oesophageal tumourigenesis via the RhoA‐MAPK signaling pathway

  2018cites this paper
• The Immune Regulatory Role of Cytokine-Induced Killer Cells Treatment on Non-Small Cell Lung Cancer Patients

  2018cites this paper
• Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy

  2018cites this paper
• The expression level of CSDAP1 in lung cancer and its clinical significance

  2018cites this paper